

A novel *NUP98-JADE2* fusion in a patient with acute myeloid leukemia resembling acute promyelocytic leukemia

Chi-Keung Cheng,¹ Hoi-Yun Chan,¹ Yuk-Lin Yung,¹ Thomas S. K. Wan,¹ Alex W. K. Leung,² Chi-Kong Li,² Ke Tian,¹ Natalie P. H. Chan,¹ Joyce S. Cheung,¹ and Margaret H. L. Ng^{1,3}

¹Blood Cancer Cytogenetics and Genomics Laboratory, Department of Anatomical and Cellular Pathology, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China; and ²Department of Pediatrics and ³State Key Laboratory of Translational Oncology, The Chinese University of Hong Kong, Hong Kong, China

Key Points

- Non-*RAR* gene rearrangements have been associated with patients with AML resembling APL but the underlying pathogenesis is unclear.
- *NUP98-JADE2* perturbs wild-type *JADE2* and retinoic acid signaling thereby contributing to an APL-like phenotype.

Acute promyelocytic leukemia (APL) is a specific subtype of acute myeloid leukemia (AML) characterized by block of differentiation at the promyelocytic stage and the presence of *PML-RARA* fusion. In rare instances, *RARA* is fused with other partners in variant APL. More infrequently, non-*RARA* genes are rearranged in AML patients resembling APL. However, the underlying disease pathogenesis in these atypical cases is largely unknown. Here, we report the identification and characterization of a *NUP98-JADE2* fusion in a pediatric AML patient showing APL-like morphology and immunophenotype. Mechanistically, we showed that *NUP98-JADE2* could impair all-trans retinoic acid (ATRA)-mediated transcriptional control and myeloid differentiation. Intriguingly, *NUP98-JADE2* was found to alter the subcellular distribution of wild-type *JADE2*, whose down-regulation similarly led to attenuated ATRA-induced responses and myeloid activation, suggesting that *NUP98-JADE2* may mediate *JADE2* inhibition. To our knowledge, this is the first report of a *NUP98-non-RAR* rearrangement identified in an AML patient mimicking APL. Our findings suggest *JADE2* as a novel myeloid player involved in retinoic acid-induced differentiation. Despite lacking a rearranged *RARA*, our findings implicate that altered retinoic acid signaling by *JADE2* disruption may underlie the APL-like features in our case, corroborating the importance of this signaling in APL pathogenesis.

Introduction

Acute promyelocytic leukemia (APL) is featured by arrested promyelocytic differentiation and the *PML-RARA* fusion.¹ In variant APL, *RARA* is fused with other partners, which dictate disease biology and treatment sensitivity.² Rarely, genomic rearrangements involving non-*RARA* genes have also been reported in patients with acute myeloid leukemia (AML) mimicking APL.²⁻⁴ Although these findings suggest that alternative pathways may mediate the promyelocytic differentiation block, the underlying mechanisms have remained obscure. The *nucleoporin 98 (NUP98)* gene encoding a component of the nuclear pore complex is rearranged in various hematological malignancies associated with poor outcomes.^{5,6} Here, we identify and characterize a novel *NUP98-JADE2* fusion in a pediatric patient with AML with morphological and immunophenotypic features resembling APL. Our findings provided mechanistic insights into how a non-*RARA* rearrangement contributes to the development of an APL-like phenotype.

Submitted 1 September 2021; accepted 1 October 2021; prepublished online as *Blood Advances* First Edition 21 October 2021; final version published online 17 January 2022. DOI 10.1182/bloodadvances.2021006064.

For data sharing, please contact the corresponding author at margaretn@cuhk.edu.hk.

The full-text version of this article contains a data supplement.

© 2022 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.




Figure 1.

Case description

The patient was a 15-month-old girl who presented with fever and gum bleeding. Physical examination showed no pallor, jaundice, petechiae, bruises, or lymphadenopathy. Complete blood count revealed a hemoglobin level of 10.3 g/dL, platelet count of $227 \times 10^9/L$, white blood cell count of $5.8 \times 10^9/L$, and neutrophil count of $0.6 \times 10^9/L$ with 19% circulating blasts. Prothrombin time and activated partial thromboplastin time were 13.9 seconds (reference, 9.5-12 seconds) and 42.7 seconds (reference, 28.2-37.4 seconds), respectively. D-dimer levels were 4982 ng/mL (reference, <500 ng/mL). Bone marrow examination showed 61% of medium- to large-sized blasts with hypergranular cytoplasm (Figure 1A). The blasts were positive for CD13, CD15, CD33, CD117, and myeloperoxidase but negative for CD34, HLA-DR, CD14, CD41, glycophorin A, and lymphoid markers (CD10/CD19/CD20/CD22/CD79a/CD2/CD3/CD5/CD7/TdT) by flow cytometry. Nearly all the blasts showed Sudan Black B positivity. A diagnosis of APL was suspected and all-trans retinoic acid (ATRA; 25 mg/m² per day) was initiated while awaiting confirmatory results.

Reverse transcription-polymerase chain reaction (RT-PCR) and fluorescence in situ hybridization failed to detect *PML-RARA* or variant *RARA* fusions. Consistently, cytogenetic studies revealed 46,XX,t(5;11)(q31;p15)[20] (Figure 1B), indicating the absence of *RARA* translocations. No somatic mutation/copy number change in 141 myeloid-related genes (supplemental Table 1) including *FLT3*, *NPM1*, *WT1*, *CEBPA*, *KIT*, and *K/NRAS* was detected by targeted next-generation sequencing. In view of the *PML-RARA* negativity, ATRA was stopped after administration for 6 days and a shortened prothrombin time (12.9 seconds) and activated partial thromboplastin time (36.8 seconds) was noted. A diagnosis of AML not otherwise specified was made and the patient was treated with the Nordic Society of Paediatric Haematology and Oncology-AML 2004 protocol.⁷ Complete remission was achieved after the first induction course. However, the patient developed cardiac failure after the sixth course of high-dose cytarabine and etoposide and died 9 months after the initial diagnosis.

Methods

Detailed experimental procedures are provided in supplemental Methods. The study was approved by the institutional review board

of the Joint Chinese University of Hong Kong-New Territories East Cluster Clinical Research Ethics Committee. Informed consent has been obtained from the parents of the patient.

Results and discussion

RNA-sequencing revealed an in-frame *NUP98-JADE2* fusion in which exon 13 of *NUP98* was fused to exon 2 of *JADE2*, which encodes a plant homeodomain zinc finger protein (Figure 1C). The full-length fusion transcript is predicted to encode a 1304-amino acid protein containing the amino-terminal portion of NUP98 plus the entire JADE2. The reciprocal *JADE2-NUP98* fusion was undetected. NUP98-JADE2 exhibited a speckled nuclear pattern in transfected HeLa cells (Figure 1D). On the contrary, wild-type JADE2 was uniformly and predominantly expressed in the nucleus. Coimmunoprecipitation studies in 293T cells showed that NUP98-JADE2 could heterodimerize with wild-type JADE2, suggesting that the fusion protein may perturb JADE2-associated pathways (Figure 1E). Accordingly, we found altered subcellular distribution of wild-type JADE2 with a speckled appearance overlapping with that of NUP98-JADE2 when the 2 proteins were overexpressed in HeLa cells (Figure 1F).

Deregulated *RARA* transcriptional control is central to APL pathogenesis.¹ The association of NUP98-JADE2 with APL-like features prompted us to examine the transcriptional properties of NUP98-JADE2 using a retinoic acid-response element (RARE)-luciferase reporter. Without ATRA, NUP98-JADE2 exerted no apparent effect on luciferase activity, whereas wild-type JADE2 mildly activated the reporter (Figure 2A). Intriguingly, NUP98-JADE2 dose-dependently inhibited ATRA-mediated transcriptional activation (Figure 2B; supplemental Figure 1). In contrast, no significant effect on luciferase induction was noted when wild-type JADE2 was overexpressed (Figure 2B). Consistent with these findings, overexpression of NUP98-JADE2 in NB4 and U937 cells diminished ATRA-induced CD11b expression, suggesting impaired myeloid differentiation (Figure 2C; supplemental Figure 2). Because NUP98-JADE2 altered wild-type JADE2 distribution and thus potentially affected its functions, we investigated the role of the wild-type protein. Interestingly, knockdown of *JADE2* by small-interfering RNAs (siRNAs) in NB4 promyelocytic leukemia cells could similarly attenuate ATRA-induced expression of CD11b and *CCAAT/enhancer binding protein ε* (*CEBPE*) (Figure 2D), a marker of terminal granulopoiesis.⁸ Further transcriptome analysis of *JADE2* knocked-down NB4 cells identified 89 genes whose expression was consistently altered (56 downregulated/

Figure 1. Identification of the *NUP98-JADE2* fusion. (A) Left, May-Grünwald-Giemsa staining of leukemic blasts in the diagnostic bone marrow (BM). The blasts were medium to large size with fine nuclear chromatin and nucleoli showing hypergranular cytoplasm. Occasional cells with 1 to 2 Auer rods (arrow) were seen but no faggot cell was detected. Right, Sudan Black B-stained positive blasts. Original magnification $\times 1000$. (B) A karyotype performed on the diagnostic BM revealed 46,XX,t(5;11)(q31;p15). (C) Upper, a schematic diagram showing NUP98, JADE2, and NUP98-JADE2 generated by ProteinPaint. The phenylalanine-glycine (FG)/glycine-leucine-phenylalanine-glycine (GLFG) repeats and Gle2-binding-sequence (GLEBS) domain in the amino-terminal portion of NUP98 are retained in the fusion protein. Lower, RT-PCR analysis of *NUP98-JADE2* (NJ) and *JADE2-NUP98* (JN) fusions in the diagnostic BM. Whole BM cells were used for the analysis. Amplification of *GAPDH* served as the control. Expected products are indicated by arrowheads. Sanger sequencing of the NJ PCR product is also shown. (D) Immunofluorescence analysis of NUP98-JADE2 and wild-type JADE2. HeLa cells were transfected with pCMV-HA-NUP98-JADE2 or pCMV-HA-JADE2, and the tagged proteins were detected as described in supplemental Methods. DAPI was used for nuclear staining. Original magnification $\times 1000$. (E) Interaction between NUP98-JADE2 and wild-type JADE2. 293T cells were transfected with the indicated Myc- and HA-tagged expression vectors. Myc-tagged proteins were immunoprecipitated and samples were analyzed by immunoblotting for NUP98-JADE2 (NJ) and JADE2 (J2) detection. Similar results were obtained when HA-tagged proteins were immunoprecipitated before immunoblotting (data not shown). (F) Altered subcellular distribution of wild-type JADE2 in the presence of NUP98-JADE2. Upper, HeLa cells were cotransfected with both pCMV-HA-NUP98-JADE2 and pCMV-HA-JADE2, and the tagged proteins were detected as mentioned previously. Original magnification $\times 1000$. Lower, HeLa cells were transfected with the indicated Myc- and HA-tagged expression vectors. Protein lysates were analyzed by immunoblotting. No apparent change in JADE2 expression was noted when NUP98-JADE2 was coexpressed.




Figure 2. Molecular characterization of NUP98-JADE2 and JADE2 in ATRA-mediated responses and myeloid differentiation. (A) HeLa cells were cotransfected with RARE reporter and the indicated pCMV-HA plasmids. EV, empty vector; NJ, NUP98-JADE2; PR, PML-RARA. Luciferase activities were determined as described in

33 upregulated) by ≥ 1.3 -fold with 2 different siRNAs in 2 independent experiments (Figure 2E; supplemental Table 2). Pathway analysis revealed that the downregulated genes were enriched in inflammatory response, myeloid activation, and cytokine production (Figure 2F). In contrast, no enriched pathway (adjusted $P < .05$) was identified from the upregulated genes. By analyzing the expression profiles of the downregulated genes in purified myeloid cells, 65% of the genes were found to exhibit increased expression (\geq twofold) during granulocytic maturation (Figure 2G). Knockdown of *JADE2* also repressed RARE-mediated gene transcription (supplemental Figure 3).

In this study, we characterized a *NUP98-JADE2* fusion in a pediatric patient with AML resembling APL and uncovered a role of *JADE2* in myeloid differentiation. *JADE2* is located at chromosome 5q31, a region frequently deleted in AML and myelodysplastic syndromes. The encoded protein has been shown to be a component of the histone acetyltransferase HBO1 complexes and a regulator of the histone demethylase LSD1/KDM1A.^{9,10} *NUP98-JADE2* is similar to other *NUP98* fusions in multiple aspects including a preserved *NUP98* amino-terminal portion, speckled nuclear distribution, aberrant *HOXA* and *CDK6* expression (supplemental Figure 4), a histone recognition domain (the plant homeodomain) in the partner, and few cooperating mutations.^{5,11,12} Concerning the latter, common AML-associated changes were absent in our case, implying that the fusion protein may be sufficient for leukemic transformation. On the other hand, *NUP98-JADE2* is distinct from other *NUP98* fusions in its association with an APL-like phenotype that is not observed with other non-*RAR* partners. However, the therapeutic efficacy of ATRA against *NUP98-JADE2* is uncertain.

Localization to the correct cellular compartment is critical for proper functioning of a protein. The *NUP98-JADE2*-induced alteration of the subcellular distribution of *JADE2* suggests that the fusion protein may act as a dominant-negative mutant to interfere with the wild-type protein. Concordantly, we observed comparable inhibitory effects of *NUP98-JADE2* overexpression and *JADE2* knockdown on ATRA-induced responses. On the other hand, how *JADE2* perturbation affects ATRA-mediated transcriptional control remains incompletely understood. Because *JADE2* is apparently a histone modulator, it is possible that the altered transcriptional response may involve epigenetic deregulation. Interestingly, *JADE2* has been shown to promote degradation of LSD1,¹⁰ which has been implicated as a

negative modulator of ATRA response.¹³ Thus, *NUP98-JADE2* may impede ATRA response through LSD1 stabilization. A previous study has reported a presumed *NUP98-JADE2* fusion in a juvenile myelomonocytic leukemia patient.¹⁴ However, the fusion breakpoints in both *NUP98* and *JADE2* were different and with concurrent *NRAS/EZH2/KAT6A* mutations, which were absent in our case.

In conclusion, we have identified a *NUP98-JADE2* fusion conferring an APL-like phenotype in an AML patient and revealed a link between impaired retinoic acid signaling and the observed phenotype. Further studies characterizing the leukemogenic properties of *NUP98-JADE2* shall shed new lights on APL pathogenesis.

Acknowledgments

The authors thank the Core Utilities of Cancer Genomics and Pathobiology (The Chinese University of Hong Kong) for providing the facilities and assistance in support of this research.

The work was partially supported by a grant from the General Research Fund program sponsored by the Research Grants Council in Hong Kong (CUHK M14108719).

Authorship

Contribution: C.-K.C. designed and performed research and wrote the manuscript; H.-Y.C., Y.-L.Y., and T.S.K.W. performed research and analyzed data; A.W.K.L. and C.-K.L. managed the patient, collected clinical data, and advised on revision of the manuscript; K.T., N.P.H.C., and J.S.C. collected clinical samples and analyzed clinicopathological data; and M.H.L.N. designed and coordinated research and advised on revision of the manuscript.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

ORCID profiles: Y.-L.Y., 0000-0002-9175-2915; C.-K.L., 0000-0002-2810-5758.

Correspondence: Margaret H. L. Ng, Blood Cancer Cytogenetics and Genomics Laboratory, Department of Anatomical and Cellular Pathology, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, NT, Hong Kong SAR, China; e-mail: margaretn@cuhk.edu.hk.

References

1. Liquori A, Ibañez M, Sargas C, Sanz MÁ, Barragán E, Cervera J. Acute promyelocytic leukemia: a constellation of molecular events around a single *PML-RARA* fusion gene [published correction appears in *Cancers (Basel)*. 2021;13(14):3440]. *Cancers (Basel)*. 2020;12(3):624.

Figure 2. (continued) supplemental Methods. (B) HeLa cells were cotransfected with RARE reporter and an increasing pCMV-HA-NUP98-JADE2 (NJ), pCMV-HA-JADE2 (J2), or the empty pCMV-HA (EV), and then treated with ATRA or DMSO for 6 hours before analysis. Results are presented as fold induction vs DMSO treatment. (A-B) $*P < .05$, $**P < .01$, and $***P < .001$ vs EV, respectively by 1-way analysis of variance followed by Dunnett test. (C) NB4 cells transduced with *NUP98-JADE2* (NJ) or control (EV) lentiviruses were treated with ATRA or DMSO. CD11b on GFP-positive cells was measured by flow cytometry. $*P < .05$ and $**P < .01$, respectively by paired *t* test. (D) Left, confirmation of *JADE2* knockdown in NB4 cells after 24 hours of siRNA transfection by quantitative RT-PCR. After the transfection, cells were treated with 0.1 μ M of ATRA or DMSO for 3 days. CD11b was measured by flow cytometry (middle) and *CEBPE* by quantitative RT-PCR and normalized to *GAPDH* (right). $**P < .01$ and $***P < .001$ vs the negative siRNA, respectively by 1-way analysis of variance followed by Dunnett test. (E) Quantitative RT-PCR to validate selected *JADE2* target genes in NB4 cells after 48 hours of siRNA transfection. $**P < .01$ vs negative siRNA by the Mann-Whitney *U* test. (A-E) Results are expressed as mean plus standard error from 3 independent experiments. (F) Pathway analysis of the 56 downregulated genes by ConsensusPathDB.¹⁵ The top 15 enriched Gene Ontology Biological Processes are shown. (G) Expression of the downregulated genes in purified polymorphonuclear cells (PMN) and granulocyte-monocyte progenitors (GMP). Data (from GSE42519) were available for 54 of the downregulated genes. Genes that are upregulated by \geq twofold (\log_2 $fc \geq 1$) in PMN are boxed.

2. Zhang X, Sun J, Yu W, Jin J. Current views on the genetic landscape and management of variant acute promyelocytic leukemia. *Biomark Res.* 2021;9(1):33.
3. Wang HY, McMahon C, Ali SM, et al. Novel FNDC3B and MECOM fusion and WT1 L378fs* 7 frameshift mutation in an acute myeloid leukaemia patient with cytomorphological and immunophenotypic features reminiscent of acute promyelocytic leukaemia. *Br J Haematol.* 2016;172(6):987-990.
4. Zhao J, Liang JW, Xue HL, et al. The genetics and clinical characteristics of children morphologically diagnosed as acute promyelocytic leukemia. *Leukemia.* 2019;33(6):1387-1399.
5. Gough SM, Slape CI, Aplan PD. NUP98 gene fusions and hematopoietic malignancies: common themes and new biologic insights. *Blood.* 2011;118(24):6247-6257.
6. Michmerhuizen NL, Kloco JM, Mullighan CG. Mechanistic insights and potential therapeutic approaches for NUP98-rearranged hematologic malignancies. *Blood.* 2020;136(20):2275-2289.
7. Hasle H, Abrahamsson J, Forestier E, et al; Nordic Society of Paediatric Haematology and Oncology (NOPHO). Gemtuzumab ozogamicin as postconsolidation therapy does not prevent relapse in children with AML: results from NOPHO-AML 2004. *Blood.* 2012;120(5):978-984.
8. Wada T, Akagi T. Role of the leucine zipper domain of CCAAT/enhancer binding protein-epsilon (C/EBP ϵ) in neutrophil-specific granule deficiency. *Crit Rev Immunol.* 2016;36(4):349-358.
9. Doyon Y, Cayrou C, Ullah M, et al. ING tumor suppressor proteins are critical regulators of chromatin acetylation required for genome expression and perpetuation. *Mol Cell.* 2006;21(1):51-64.
10. Han X, Gui B, Xiong C, et al. Destabilizing LSD1 by Jade-2 promotes neurogenesis: an antibraking system in neural development. *Mol Cell.* 2014;55(3):482-494.
11. Schmoellerl J, Barbosa IAM, Eder T, et al. CDK6 is an essential direct target of NUP98 fusion proteins in acute myeloid leukemia. *Blood.* 2020;136(4):387-400.
12. Terlecki-Zaniewicz S, Humer T, Eder T, et al. Biomolecular condensation of NUP98 fusion proteins drives leukemogenic gene expression. *Nat Struct Mol Biol.* 2021;28(2):190-201.
13. Schenk T, Chen WC, Göllner S, et al. Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia. *Nat Med.* 2012;18(4):605-611.
14. Schwartz JR, Ma J, Lamprecht T, et al. The genomic landscape of pediatric myelodysplastic syndromes. *Nat Commun.* 2017;8(1):1557.
15. Herwig R, Hardt C, Lienhard M, Kamburov A. Analyzing and interpreting genome data at the network level with ConsensusPathDB. *Nat Protoc.* 2016;11(10):1889-1907.